HPV vaccine pilot shows promise for High-Risk groups

NCT ID NCT06588257

Completed Prevention Sponsor: Fundación Huésped Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed pilot study enrolled 101 transgender women and men who have sex with men to see how acceptable the HPV vaccine (Gardasil 9) is in these groups. Participants received three doses over six months, and researchers tracked how many completed the series and how common anal HPV infections were. The goal is to improve vaccine uptake and reduce HPV-related cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPV vaccine (Gardasil 9)
What this could lead to: If successful, this could help improve HPV vaccination rates and reduce anal cancer risk in these groups.
What could go wrong: This is a small, completed pilot study focused on acceptability, not on proving the vaccine prevents disease. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV

Contacts and locations

Locations

Fundación Huésped

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1427CEA, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.